Variant: NM_000540.2(RYR1):c.7097C>G (p.Pro2366Arg)

CA024705

133186 (ClinVar)

Gene: RYR1

Condition: malignant hyperthermia, susceptibility to, 1

Inheritance Mode: Autosomal dominant inheritance

UUID: 05464467-9cab-4ba7-9f39-1f494cb952f1

Approved on: 2023-04-06

Published on: 2023-04-06

HGVS expressions

NM_000540.2:c.7097C>G
NM_000540.2(RYR1):c.7097C>G (p.Pro2366Arg)
NC_000019.10:g.38499704C>G
CM000681.2:g.38499704C>G
NC_000019.9:g.38990344C>G
CM000681.1:g.38990344C>G
NC_000019.8:g.43682184C>G
NG_008866.1:g.71005C>G
ENST00000599547.6:n.7097C>G
ENST00000359596.8:c.7097C>G
ENST00000355481.8:c.7097C>G
ENST00000359596.7:n.7097C>G
ENST00000360985.7:c.7094C>G
ENST00000594335.5:n.549C>G
NM_001042723.1:c.7097C>G
NM_000540.3:c.7097C>G
NM_001042723.2:c.7097C>G
NM_000540.3(RYR1):c.7097C>G (p.Pro2366Arg)

Uncertain Significance

• Met criteria codes: PS4_Supporting PM1 PP3_Moderate

• Not Met criteria codes: BA1 BS1 BP4

Expert Panel

Malignant Hyperthermia Susceptibility VCEP

Criteria Specification Information

Evidence submitted by expert panel

Malignant Hyperthermia Susceptibility VCEP

This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of proline with arginine at codon 2366 of the RYR1 protein, p.(Pro2366Arg). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in two unrelated individuals who have a personal or family history of a malignant hyperthermia reaction without positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) results, PS4_Supporting (PMID: 16732084, PMID:31559918). No functional studies were identified for this variant. This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score >0.85 (0.88) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as a Variant of Unknown Significance. Criteria implemented: PS4_Supporting, PM1, PP3_Moderate.

Met criteria codes

• PS4_Supporting: This variant has been reported in two unrelated individuals who have a personal or family history of a malignant hyperthermia reaction without positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) results, PS4_Supporting (PMID: 16732084, PMID:31559918).
• PM1: This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704).
• PP3_Moderate: A REVEL score >0.85 (0.88) supports a pathogenic status for this variant, PP3_Moderate.

Not Met criteria codes

• BA1: No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
• BS1: No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
• BP4: No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline